Cogent Biosciences, Inc. Amortization of Debt Issuance Costs and Discounts
Cogent Biosciences, Inc. (COGT) reported Amortization of Debt Issuance Costs and Discounts of $562.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-10
- Cogent Biosciences, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $284.00K, a 350.79% increase year-over-year.
- Cogent Biosciences, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $278.00K.
- Cogent Biosciences, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $238.00K.
- Cogent Biosciences, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $300.00K.
- Cogent Biosciences, Inc. amortization of debt issuance costs and discounts for fiscal 2025 was $601.00K.
- Cogent Biosciences, Inc. amortization of debt issuance costs and discounts for fiscal 2024 was $0.00.
- Cogent Biosciences, Inc. amortization of debt issuance costs and discounts for fiscal 2023 was $0.00.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $284.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $562.00K 10-Q · filed 2026-08-10 | $800.00K derived: sum of 3 quarters · filed 2026-08-10 | $1.10M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $278.00K 10-Q · filed 2026-05-05 | $516.00K derived: sum of 2 quarters · filed 2026-05-05 | $816.00K derived: sum of 3 quarters · filed 2026-05-05 | $879.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $538.00K derived: sum of 2 quarters · filed 2026-02-17 | $601.00K derived: sum of 3 quarters · filed 2026-08-10 | $601.00K 10-K · filed 2026-02-17 |
| 2025-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $363.00K derived: sum of 2 quarters · filed 2026-08-10 | $363.00K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $63.00K 10-Q · filed 2026-08-10 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-17 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |